Literature DB >> 23562812

Lipopolysaccharide clearance, bacterial clearance, and systemic inflammatory responses are regulated by cell type-specific functions of TLR4 during sepsis.

Meihong Deng1, Melanie J Scott, Patricia Loughran, Gregory Gibson, Chhinder Sodhi, Simon Watkins, David Hackam, Timothy R Billiar.   

Abstract

The morbidity associated with bacterial sepsis is the result of host immune responses to pathogens, which are dependent on pathogen recognition by pattern recognition receptors, such as TLR4. TLR4 is expressed on a range of cell types, yet the mechanisms by which cell-specific functions of TLR4 lead to an integrated sepsis response are poorly understood. To address this, we generated mice in which TLR4 was specifically deleted from myeloid cells (LysMTLR4KO) or hepatocytes (HCTLR4KO) and then determined survival, bacterial counts, host inflammatory responses, and organ injury in a model of cecal ligation and puncture (CLP), with or without antibiotics. LysM-TLR4 was required for phagocytosis and efficient bacterial clearance in the absence of antibiotics. Survival, the magnitude of the systemic and local inflammatory responses, and liver damage were associated with bacterial levels. HCTLR4 was required for efficient LPS clearance from the circulation, and deletion of HCTLR4 was associated with enhanced macrophage phagocytosis, lower bacterial levels, and improved survival in CLP without antibiotics. Antibiotic administration during CLP revealed an important role for hepatocyte LPS clearance in limiting sepsis-induced inflammation and organ injury. Our work defines cell type-selective roles for TLR4 in coordinating complex immune responses to bacterial sepsis and suggests that future strategies for modulating microbial molecule recognition should account for varying roles of pattern recognition receptors in multiple cell populations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23562812      PMCID: PMC3644895          DOI: 10.4049/jimmunol.1300496

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  60 in total

1.  Combination of imipenem and TAK-242, a Toll-like receptor 4 signal transduction inhibitor, improves survival in a murine model of polymicrobial sepsis.

Authors:  Takuryu Sha; Yuji Iizawa; Masayuki Ii
Journal:  Shock       Date:  2011-02       Impact factor: 3.454

2.  Early enhanced local neutrophil recruitment in peritonitis-induced sepsis improves bacterial clearance and survival.

Authors:  Florin L Craciun; Elizabeth R Schuller; Daniel G Remick
Journal:  J Immunol       Date:  2010-11-01       Impact factor: 5.422

3.  Both TRIF- and MyD88-dependent signaling contribute to host defense against pulmonary Klebsiella infection.

Authors:  Shanshan Cai; Sanjay Batra; Li Shen; Nobuko Wakamatsu; Samithamby Jeyaseelan
Journal:  J Immunol       Date:  2009-10-21       Impact factor: 5.422

Review 4.  Innate immune signaling in cardiac ischemia.

Authors:  Fatih Arslan; Dominique P de Kleijn; Gerard Pasterkamp
Journal:  Nat Rev Cardiol       Date:  2011-03-29       Impact factor: 32.419

5.  The Toll-like receptor 4 agonist monophosphoryl lipid a augments innate host resistance to systemic bacterial infection.

Authors:  Christopher D Romero; Tushar K Varma; Jason B Hobbs; Aimee Reyes; Brandon Driver; Edward R Sherwood
Journal:  Infect Immun       Date:  2011-06-06       Impact factor: 3.441

Review 6.  Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis.

Authors:  Mark Tidswell; Steven P LaRosa
Journal:  Expert Rev Anti Infect Ther       Date:  2011-05       Impact factor: 5.091

7.  A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis.

Authors:  Todd W Rice; Arthur P Wheeler; Gordon R Bernard; Jean-Louis Vincent; Derek C Angus; Naoki Aikawa; Ignace Demeyer; Stephen Sainati; Nicholas Amlot; Charlie Cao; Masayuki Ii; Hideyasu Matsuda; Kouji Mouri; Jon Cohen
Journal:  Crit Care Med       Date:  2010-08       Impact factor: 7.598

8.  Impaired Cd14 and Cd36 expression, bacterial clearance, and Toll-like receptor 4-Myd88 signaling in caveolin-1-deleted macrophages and mice.

Authors:  Tsung-Huang Tsai; Shu-Fen Chen; Tai-Yu Huang; Chun-Fu Tzeng; Ann-Shyn Chiang; Yu Ru Kou; Tzong-Shyuan Lee; Song-Kun Shyue
Journal:  Shock       Date:  2011-01       Impact factor: 3.454

9.  Endotoxin uptake in mouse liver is blocked by endotoxin pretreatment through a suppressor of cytokine signaling-1-dependent mechanism.

Authors:  Melanie J Scott; Shubing Liu; Richard A Shapiro; Yoram Vodovotz; Timothy R Billiar
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

10.  Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial.

Authors:  Dinna N Cruz; Massimo Antonelli; Roberto Fumagalli; Francesca Foltran; Nicola Brienza; Abele Donati; Vincenzo Malcangi; Flavia Petrini; Giada Volta; Franco M Bobbio Pallavicini; Federica Rottoli; Francesco Giunta; Claudio Ronco
Journal:  JAMA       Date:  2009-06-17       Impact factor: 56.272

View more
  87 in total

1.  miR-15a/16 regulates macrophage phagocytosis after bacterial infection.

Authors:  Hyung-Geun Moon; Jincheng Yang; Yijie Zheng; Yang Jin
Journal:  J Immunol       Date:  2014-09-26       Impact factor: 5.422

Review 2.  How the Innate Immune System Senses Trouble and Causes Trouble.

Authors:  Takashi Hato; Pierre C Dagher
Journal:  Clin J Am Soc Nephrol       Date:  2014-11-20       Impact factor: 8.237

3.  Eliciting inflammation enables successful rehabilitative training in chronic spinal cord injury.

Authors:  Abel Torres-Espín; Juan Forero; Keith K Fenrich; Ana M Lucas-Osma; Aleksandra Krajacic; Emma Schmidt; Romana Vavrek; Pamela Raposo; David J Bennett; Phillip G Popovich; Karim Fouad
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

4.  C23, an oligopeptide derived from cold-inducible RNA-binding protein, suppresses inflammation and reduces lung injury in neonatal sepsis.

Authors:  Naomi-Liza Denning; Weng-Lang Yang; Laura Hansen; Jose Prince; Ping Wang
Journal:  J Pediatr Surg       Date:  2019-01-04       Impact factor: 2.545

5.  Protection of baicalin against lipopolysaccharide induced liver and kidney injuries based on 1H NMR metabolomic profiling.

Authors:  Shanting Liao; Pei Li; Junsong Wang; Qian Zhang; Dingqiao Xu; Minghua Yang; Lingyi Kong
Journal:  Toxicol Res (Camb)       Date:  2016-05-24       Impact factor: 3.524

6.  Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis.

Authors:  Christopher W Seymour; Jason N Kennedy; Shu Wang; Chung-Chou H Chang; Corrine F Elliott; Zhongying Xu; Scott Berry; Gilles Clermont; Gregory Cooper; Hernando Gomez; David T Huang; John A Kellum; Qi Mi; Steven M Opal; Victor Talisa; Tom van der Poll; Shyam Visweswaran; Yoram Vodovotz; Jeremy C Weiss; Donald M Yealy; Sachin Yende; Derek C Angus
Journal:  JAMA       Date:  2019-05-28       Impact factor: 56.272

Review 7.  The role of the liver in sepsis.

Authors:  Jun Yan; Song Li; Shulin Li
Journal:  Int Rev Immunol       Date:  2014-03-10       Impact factor: 5.311

8.  Anti-inflammatory effects of miR-21 in the macrophage response to peritonitis.

Authors:  Rebecca Elise Barnett; Daniel J Conklin; Lindsey Ryan; Robert C Keskey; Vikram Ramjee; Ernesto A Sepulveda; Sanjay Srivastava; Aruni Bhatnagar; William G Cheadle
Journal:  J Leukoc Biol       Date:  2015-09-17       Impact factor: 4.962

9.  Blue Light Enhances Bacterial Clearance and Reduces Organ Injury During Sepsis.

Authors:  Anthony J Lewis; Xianghong Zhang; John E Griepentrog; Du Yuan; Richard D Collage; Paul K Waltz; Derek C Angus; Brian S Zuckerbraun; Matthew R Rosengart
Journal:  Crit Care Med       Date:  2018-08       Impact factor: 7.598

10.  A novel PINK1- and PARK2-dependent protective neuroimmune pathway in lethal sepsis.

Authors:  Rui Kang; Ling Zeng; Yangchun Xie; Zhengwen Yan; Borong Zhou; Lizhi Cao; Daniel J Klionsky; Kevin J Tracey; Jianhua Li; Haichao Wang; Timothy R Billiar; Jianxin Jiang; Daolin Tang
Journal:  Autophagy       Date:  2016-10-18       Impact factor: 16.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.